Current phase: Stage 3: Advanced Momentum / Potential Distribution
The NYSE-listed Charles River Laboratories, Inc. (CRL - Business Profile) is in a strong, accelerated uptrend after advancing from its May low near $146.20 to above $310. On Oct. 5, the stock rose roughly 7.1% to 7.6%, reached a fresh 52-week high near $312.26, and traded above its average volume. MACD is bullish and RSI near 67 is strong, but the stock is increasingly extended. The setup favors holding existing positions rather than chasing fresh entries.
Chart Analysis & Price Action Assessment
- Overall trend: The short-, medium- and long-term trends are strongly bullish. CRL is making new 52-week highs and remains well above its major moving averages.
- Recent price behavior: CRL opened near $292.05, traded between approximately $292.02 and $312.26, and closed around $310 to $311 after gaining roughly 7.1% to 7.6%. Data vendors differ on the exact closing print, but all confirm a substantial one-day advance.
- Breakout behavior: The stock cleared the previous 52-week-high zone near $303.31 and established a new high above $312. This is technically bullish, but the acceleration increases short-term pullback risk.
- Candlestick behavior: The Oct. 5 session had a very wide range of roughly $20 and closed near its high. That shows strong demand, although a large one-day extension after a multi-month rise can mark late-stage momentum.
- Moving-average structure: Price is substantially above the 50-day and 200-day moving averages. This confirms strength but also indicates that the stock is extended from trend support.
| Technical Zone | Approximate Level | Interpretation |
|---|---|---|
| Immediate support | $303.31 to $306.30 | Prior 52-week-high zone and first breakout-retest area. |
| Key support | $292.02 to $296.00 | Oct. 5 session low and first meaningful pullback zone. |
| Secondary support | $282 to $288 | Short-term consolidation and trend-support region. |
| Intermediate support | $260 to $270 | Deeper pullback zone if the breakout fails. |
| Immediate resistance | $312.05 to $312.26 | Current 52-week high and first price-discovery barrier. |
| Psychological resistance | $320 to $325 | Potential extension zone after a confirmed high breakout. |
| Higher resistance | $335 to $340 | Projected price-discovery zone if momentum accelerates. |
Volume & Volatility Analysis
- Volume: Oct. 5 volume was reported around 1.3 million shares, compared with an average near 0.92 to 0.97 million shares. This was roughly 35% to 40% above average.
- Volume-price relationship: The breakout occurred on above-average volume and closed near the high, providing better confirmation than a low-volume rally. However, volume was not extreme enough by itself to remove the risk of short-term profit-taking.
- Volatility: Volatility was high. The session range was approximately $20.24, or about 6.5% of the closing price. CRL also has a reported beta near 1.40.
- Momentum indicators: RSI was approximately 67, indicating strong momentum but approaching overbought conditions. MACD near 2.54 generated a buy signal, while Williams %R near 3.6 indicated an overbought short-term state.
- Current interpretation: CRL has genuine momentum confirmation, but the combination of a large one-day move, new annual high and overbought oscillator readings makes a pause or pullback increasingly likely.
Phase Classification
Stage 3: Advanced Momentum / Potential Distribution
- Price action: CRL has advanced rapidly from approximately $146 to above $310 and is now trading at a new annual high.
- Trend structure: Price is far above major moving averages, confirming a powerful trend but also a significant distance from normal trend support.
- Volume: Above-average volume on the breakout confirms meaningful participation.
- Volatility: High, with a one-day range near 6.5% of price.
- Momentum: Strong but increasingly extended. RSI near 67 and bullish MACD support continuation, while Williams %R warns of overbought conditions.
Stage 3 is the most appropriate risk classification. This does not mean that the uptrend must end immediately; it means that the stock has moved beyond a low-risk accumulation entry. A healthy consolidation above $303 to $306 would improve the structure, whereas a break back below that zone would suggest a failed or weakening breakout.
Breakdown Risk
A decisive close below $303.31 to $306.30 would undermine the fresh-high breakout and could expose CRL to $292.02 to $296.00, followed by the $282 to $288 intermediate support zone. Because the stock has risen rapidly, corrections can be sharp even if the longer-term thesis remains positive.
Final Summary & Recommended Action
Based on the magnitude of the advance, breakout behavior, volume, volatility and momentum, CRL is currently in Stage 3: Advanced Momentum / Potential Distribution.
Key Observations
- Trend Direction: Strongly bullish, with a new 52-week high.
- Volume Behavior: Above average on the breakout, providing confirmation but not removing pullback risk.
- Volatility: High; the latest daily range was approximately 6.5% of price.
- Momentum: Strong but extended; RSI near 67, MACD bullish and Williams %R overbought.
- Immediate Support: $303.31 to $306.30.
- Key Support: $292.02 to $296.00.
- Secondary Support: $282 to $288.
- Immediate Resistance: $312.05 to $312.26.
- Psychological Resistance: $320 to $325.
- Higher Extension: $335 to $340.
Suggested Strategy
- Fresh buyers should avoid chasing CRL after a 7%+ daily move to a new 52-week high.
- Existing holders may continue holding but should consider tighter trailing-risk controls because the stock is extended.
- A controlled pullback that holds $303.31 to $306.30 would be healthier than another vertical advance and could create a continuation base.
- A sustained move above $312.26 with strong volume could open the way toward $320 to $325.
- A close below $303.31 to $306.30 would weaken the breakout and increase the probability of a move toward $292.02 to $296.00.
- Track biopharma funding, laboratory-services demand, discovery and safety-assessment bookings, operating margins, client concentration, pharmaceutical R&D budgets and management guidance.
Final Action Plan
- Current stance: HOLD / DO NOT CHASE.
- Existing holders may hold with tighter trailing risk management while price remains above $303.31 to $306.30.
- Fresh buyers should wait for a controlled retest of $303 to $306 or for a new base to form above the breakout zone.
- A sustained, high-volume move above $312.26 would support continuation toward $320 to $325.
- A break below $303.31 to $306.30 would weaken the breakout and increase downside risk toward $292.02 to $296.00.
- A deeper move below $282 to $288 would represent a more meaningful momentum reset and should not be ignored.
This analysis is educational and based on publicly reported market data available through Oct. 5, 2026. It is not investment advice. Confirm current price, volume, company disclosures and your own risk tolerance before trading or investing.